CSF biomarkers for mild cognitive impairment (Q30953185)

27 June 2017

1 reference

title

CSF biomarkers for mild cognitive impairment (English)

1 reference

mild cognitive impairment

27 June 2017

0 references

1 reference

based on heuristic

inferred from title

cognitive dysfunction

1 reference

Blennow K

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Journal of Internal Medicine

27 June 2017

published in

1 reference

27 June 2017

volume

256

1 reference

27 June 2017

1 reference

27 June 2017

page(s)

224-234

1 reference

Observations on the brains of demented old people

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Clinical heterogeneity of probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Long-term follow-up of patients who received 10,098 spinal anesthetics; syndrome of decreased intracranial pressure (headache and ocular and auditory difficulties).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Cerebrospinal Fluid ‘Neuronal Thread Protein’ Comes from Serum by Passage over the Blood-Brain Barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01368.X

10.1111/J.1365-2796.2004.01368.X

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference